135 related articles for article (PubMed ID: 18503754)
1. Using spectral moments of spiral networks based on PSA/mass spectra outcomes to derive quantitative proteome-disease relationships (QPDRs) and predicting prostate cancer.
Ferino G; González-Díaz H; Delogu G; Podda G; Uriarte E
Biochem Biophys Res Commun; 2008 Jul; 372(2):320-5. PubMed ID: 18503754
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Proteome-Property Relationships (QPPRs). Part 1: finding biomarkers of organic drugs with mean Markov connectivity indices of spiral networks of blood mass spectra.
Cruz-Monteagudo M; Munteanu CR; Borges F; Cordeiro MN; Uriarte E; González-Díaz H
Bioorg Med Chem; 2008 Nov; 16(22):9684-93. PubMed ID: 18951807
[TBL] [Abstract][Full Text] [Related]
3. New circulating biomarkers for prostate cancer.
Bensalah K; Lotan Y; Karam JA; Shariat SF
Prostate Cancer Prostatic Dis; 2008; 11(2):112-20. PubMed ID: 17998918
[TBL] [Abstract][Full Text] [Related]
4. Molecular markers of prostate cancer.
Bradford TJ; Tomlins SA; Wang X; Chinnaiyan AM
Urol Oncol; 2006; 24(6):538-51. PubMed ID: 17138135
[TBL] [Abstract][Full Text] [Related]
5. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Sardana G; Jung K; Stephan C; Diamandis EP
J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
[TBL] [Abstract][Full Text] [Related]
6. Serum markers for prostate cancer: a rational approach to the literature.
Steuber T; O'Brien MF; Lilja H
Eur Urol; 2008 Jul; 54(1):31-40. PubMed ID: 18243505
[TBL] [Abstract][Full Text] [Related]
7. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
8. 3D-MEDNEs: an alternative "in silico" technique for chemical research in toxicology. 2. quantitative proteome-toxicity relationships (QPTR) based on mass spectrum spiral entropy.
Cruz-Monteagudo M; González-Díaz H; Borges F; Dominguez ER; Cordeiro MN
Chem Res Toxicol; 2008 Mar; 21(3):619-32. PubMed ID: 18257557
[TBL] [Abstract][Full Text] [Related]
9. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA
J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer biomarker discovery using high performance mass spectral serum profiling.
Oh JH; Lotan Y; Gurnani P; Rosenblatt KP; Gao J
Comput Methods Programs Biomed; 2009 Oct; 96(1):33-41. PubMed ID: 19423179
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives.
Srigley JR; Amin M; Boccon-Gibod L; Egevad L; Epstein JI; Humphrey PA; Mikuz G; Newling D; Nilsson S; Sakr W; Wheeler TM; Montironi R
Scand J Urol Nephrol Suppl; 2005 May; (216):8-19. PubMed ID: 16019756
[TBL] [Abstract][Full Text] [Related]
12. Blood biomarkers for prostate cancer detection and prognosis.
Shariat SF; Karam JA; Roehrborn CG
Future Oncol; 2007 Aug; 3(4):449-61. PubMed ID: 17661720
[TBL] [Abstract][Full Text] [Related]
13. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network.
Stephan C; Meyer HA; Cammann H; Nakamura T; Diamandis EP; Jung K
Biol Chem; 2006 Jun; 387(6):801-5. PubMed ID: 16800743
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
Fitzpatrick JM; Banu E; Oudard S
BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection.
Payne SR; Serth J; Schostak M; Kamradt J; Strauss A; Thelen P; Model F; Day JK; Liebenberg V; Morotti A; Yamamura S; Lograsso J; Sledziewski A; Semjonow A
Prostate; 2009 Sep; 69(12):1257-69. PubMed ID: 19459176
[TBL] [Abstract][Full Text] [Related]
16. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era.
Bickers B; Aukim-Hastie C
Anticancer Res; 2009 Aug; 29(8):3289-98. PubMed ID: 19661347
[TBL] [Abstract][Full Text] [Related]
17. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
18. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.
Shariat SF; Karam JA; Margulis V; Karakiewicz PI
BJU Int; 2008 Mar; 101(6):675-83. PubMed ID: 17941930
[TBL] [Abstract][Full Text] [Related]
19. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
[TBL] [Abstract][Full Text] [Related]
20. [The density of prostate specific antigen of the transition zone as an early predictor of prostate cancer].
Topuzov ME; Prialukhin AE; Zhivov AV; Plekhanov AIu
Vestn Khir Im I I Grek; 2008; 167(6):119-21. PubMed ID: 19241832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
